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Abstract 1 
Background: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be 2 
a potential candidate that could influence pulmonary function in ABVD (doxorubicin, 3 
bleomycin, vinblastin, dacarbasine) – treated Hodgkin lymphoma (HL) patients.   4 
Patients and Methods: We hypothesized that the BLMH gene SNP A1450G (rs1050565) 5 
influences BLMH activity and late pulmonary toxicity. St. George Respiratory Questionnaire, 6 
lung scintigraphy and spirometry were used to determine lung function. TaqMan genotyping 7 
assay was used to determine genotype distribution of 131 previously treated HL patients. 8 
Results: Significantly more favorable results were seen in the wild-type A/A genotype group 9 
than those in the group containing the mutated allele: A/G+G/G in retrospective pulmonary 10 
tests of ABVD treated patients.  11 
Conclusion: Besides limitations of the current study, bleomycin pharmacokinetics should be 12 
further evaluated in patients with BLMH variations, hence identify those cases even in the 13 
frontline setting, where bleomycin should be omitted and replaced with targeted therapy. 14 
Keywords: Hodgkin lymphoma; bleomycin; bleomycin hydrolase; polymorphism; 15 
pulmonary toxicity 16 
17 
 3 
Introduction 1 
The survival rates of Hodgkin lymphoma (HL) patients have significantly improved over the 2 
past decades. Hence, reducing late toxicity along with better survival is of interest. Currently 3 
used standard of care, first line therapy, bleomycin-containing ABVD (doxorubicin, 4 
bleomycin, vinblastin, dacarbasin) and BEACOPP (bleomycin, etoposide, doxorubicin, 5 
cyclophosphamide, vincristine, procarbazine, prednisone) have been reported to produce 6 
bleomycin- induced lung injury in 20-46 % of patients. [1,2]  7 
Bleomycin, a glycopeptides antibiotic, was discovered in 1966, derived from Streptomyces 8 
verticillus, and later came to be used as an antitumor agent due to its capacity to induce 9 
reactive oxygen radicals. [3] Bleomycin is mainly excreted by the kidneys; however, it can 10 
also be eliminated by its specific deactivating enzyme, bleomycin hydrolase (BLMH). [4] 11 
Despite being an effective chemotherapeutic agent, its use is limited by its potentially life-12 
threatening pulmonary toxicity. [5] Its toxic effect is related to its free radical-producing 13 
capacity, while its lung specificity is related to the fact that BLMH is absent in the lungs. [2] 14 
Risk factors for lung damage are as follows: cumulative bleomycin dose, chest irradiation, 15 
age, renal function, smoking, use of colony stimulating factors, and route of administration 16 
(intravenous (iv.) or intramuscular (im.)). 17 
Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential 18 
candidate that influences pulmonary function. Single nucleotide polymorphisms (SNP) 19 
A1450G is located in the C-terminal region, which is responsible for the enzymatic activity 20 
[6,7], and this SNP leads to the substituition of isoleucin as amino acid residue 443 by valine, 21 
thus changing aminopeptidase activity. [8] Although the exact effect of this SNP on the 22 
enzymatic activity of BLMH is unknown, it appears to influence the level of bleomycin-23 
induced DNA damage. [9] No similar data about BLMH is available either in HL tissue in 24 
vitro, or among HL patients. [2] 25 
We hypothesize that BLMH gene SNP A1450G influences BLMH activity and by an altered 26 
metabolism of bleomycin, differences can be seen at the risk of bleomycin-induced toxicity 27 
 4 
appearance. This study aims to evaluate treatment-related long-term pulmonary side effects 1 
and their correlation with genetic distribution. 2 
 3 
Patients and Methods 4 
The current pulmonary function of HL patients previously treated at the Department of 5 
Hematology, University of Debrecen (UD), was investigated over a one-year-period as 6 
previously reported. [10] Briefly, after collecting epidemiological/ clinicopathological data 7 
(gender, age at time of diagnosis, clinical stage, histological subtypes, smoking history, 8 
pretreatment kidney function, treatment modality, chemotherapy regimen, radiotherapy 9 
modality and elapsed time from treatment), pulmonary function assessed  using the St. 10 
George Respiratory Questionnaire (SGRQ), dynamic inhalation lung scintigraphy and 11 
spirometry, retrospectively at the outpatients clinic during their follow- up at a certain time 12 
point. SGRQ scores range between 0 and 100. The higher the value, the worse patient-13 
reported quality of life. Spirometry results were calculated as a percentage of healthy, age and 14 
gender matched controls. To investigate possible functional deviations dynamic inhalation 15 
lung scintigraphy was performed. After inhalation, clearance of technetium-99m diethylene 16 
triamine penta-acetic acid (DTPA) was compared to the normal values of the corresponding 17 
age and lung side. The lower the result, the more severe the membrane lesion was. 18 
After approval of the “Local Research Ethics Committee, Faculty of Medicine, University of 19 
Debrecen” and written informed consent of the patients, already surveyed, peripheral blood 20 
samples were collected of previously treated HL patients, whose current pulmonary function 21 
test results were already available. Patient samples were blinded by receiving unique codes, 22 
therefore during identifying their genotype authors weren’t aware pf patients’ identity. 23 
Genomic DNA was isolated from peripheral blood samples using MagnaPure 96 System 24 
(Roche) according to manufacturer’s protocol. SNP A1450G (rs1050565) of the BLMH gene 25 
was genotyped using TaqMan genotyping assays (Lifetechnologies). Measurements and 26 
genotype calling were performed on QuantStudio 12K flex instrument (Lifetechnologies) at 27 
the Genomic Medicine and Bioinformatic Core Facility of UD. The QC of the genotyping 28 
 5 
calls were >98% and the technical duplicates gave the same genotype in every cases. 1 
The genotype results of BLMH were then compared with current pulmonary status, to 2 
conclude, whether BLMH SNP A1450G correlates with long-term pulmonary toxicity.  3 
Statistical analysis was performed using SPPS version 22 software. Analysis was done using 4 
the Mann-Whitney test, Chi-square test and linear regression analysis as appropriate. 5 
Correlations were considered significant if p<0.05. 6 
 7 
Results 8 
Out of the total cohort of 131 previously treated HL patients, bleomycin was included in the 9 
treatment of 102 patients (ABVD, BEACOPP, COPP/ABV (cyclophophamide, vincristin, 10 
prednisone, procarbazine, doxorubicin, bleomycin, vinblastin), relapsed/ refractory patients). 11 
The treatment of the remaining 29 patients excluded bleomycin (irradiation only, COPP 12 
(cyclophophamide, vincristin, prednisone, procarbazine), CVPP (cyclophophamide, 13 
vinblastine, prednisone, procarbazine)), thus representing a control group. Out of the 102 14 
bleomycin-treated patients 68 received ABVD chemotherapy alone. Median bleomycin dose 15 
and time elapsed from treatment completion differed significantly in the treatment groups. 16 
Other factors (smoking, age, bleomycin dose, chest irradiation, kidney function, use of colony 17 
stimulating factors) that could potentially affect lung function were equally represented in all 18 
investigated subgroups with no significant differences. Further patient characteristics are 19 
detailed in Table 1. 20 
Patient samples were collected from these previously treated HL patients, whose BLMH 21 
A1450G genotype distribution was determined. Homozygous wild-type A/A genotype was 22 
found in 72 patients (55.0%), while 44 patients (33.6%) had heterozygous A/G and 15 23 
patients (11.5%) had homozygous mutated G/G genotype, where “A” is the wild-type (allele 24 
frequency: 71.8%) and “G” is the mutated allele (allele frequency: 28.2%). (Table 2.)  Our 25 
results were comparable to the NCBI SNP database for BLMH SNP A1450G. (Table 3.) 26 
Allele frequencies were in Hardy-Weinberg equilibrium. G/G genotype group alone would 27 
have been too small for relevant statistical analysis, therefore patients were then subdivided 28 
 6 
into subgroups: one containing the mutated allele: A/G+G/G (45.1%) and the other 1 
homogenous for the wild-type allele: A/A (55.0%), thus demonstrating the possible role of the 2 
wild-type “A” and mutated “G” allele.  3 
Factors, which could potentially affect lung function, were equally represented between the 4 
subgroups containing the mutated allele (A/G+G/G) and those homogenous for the wild-type 5 
allele (A/A) even within the investigated treatment groups with no significant differences. 6 
(Table 4.)  7 
All bleomycin- treated patients (n=102) had more favorable lung function test results in the 8 
A/A genotype group, with every investigated test method with significant differences in the 9 
forced vital capacity results (FVC), p=0.006. (data not shown) 10 
When focusing on patients who received ABVD regimen (n=68) alone, significantly more 11 
favorable results were seen in the A/A genotype group, with every investigated test method. 12 
The SGRQ score was significantly more favorable in the A/A genotype group (11.90 pts. vs. 13 
4.20 pts., p=0.035). Right-sided lung scintigraphy results were also significantly more 14 
favorable in the A/A genotype group (74.81 vs. 57.56, p=0.045). Among spirometry results 15 
FVC (p=0.020) and forced expiratory volume in 1 s (FEV1) results were significantly more 16 
favorable (p=0.028) in the A/A genotype group. A linear regression analysis also confirmed 17 
these results. (Fig 1.) 18 
As a control group (n=29), patients treated with agents excluding bleomycin (irradiation or 19 
chemotherapeutic regimens not containing bleomycin) were tested with no significant 20 
differences between A/G+G/G and A/A genotype groups. (Fig 2.) 21 
 22 
Discussion 23 
Bleomycin-induced lung injury is a valid limitation of current standard of care in HL patients. 24 
BLMH gene SNP A1450G polymorphism led to significant differences in the follow-up 25 
pulmonary test results of ABVD-treated HL patients. The authors believe, that the observed 26 
difference in the ABVD only group is due to the genotype differences, and not due to other 27 
 7 
factors, that could possibly affect pulmonary function, since these factors were equally 1 
represented between the treatment groups and also in the control group.  2 
Bleomycin can be administered 10mg/m2 dose iv. or im.. In our institution patients are treated 3 
exclusively im. and dose is maximized at 15 mg. Given a median 120 mg/m2 bleomycin dose, 4 
a maximum of 180 mg bleomycin could have been administered. Only one acute bleomycin- 5 
induced lung injury was documented among the investigated patients. While the half-life of 6 
bleomycin is comparable with iv. and im. administration (2-3 hours), peak plasma level of im. 7 
administration is only one tenth of iv. administration, thus providing basis of barely lack of 8 
acute pulmonary toxicity. [11]  9 
BLMH gene SNP A1450G has been investigated previously in testicular germ-cell cancer 10 
(TC) patients treated with bleomycin in correlation with survival data. Mutant variant (G/G) 11 
genotype was associated with decreased survival compared to the heterozygous (A/G) and the 12 
wild-type variants (A/A) [12]. SNP A1450G was also investigated in correlation with 13 
pulmonary toxicity of TC patients in a subsequent study. [13] Interestingly, no association 14 
was found of gene polymorphism either with acute bleomycin-induced pneumonitis or with 15 
pulmonary function tests performed during treatment. Because the serum half-life of 16 
bleomycin is relatively short, authors explained the lack of correlation with barely injured 17 
kidney function, when the effect of altered BLMH activity is negated by the rapid elimination 18 
of bleomycin. The fact, that homozygous variant (G/G) TC patients in the Dutch-study were 19 
associated with decreased survival could be explained by the fact, that in this genotype group, 20 
there were more patients with refractory disease, than in other groups. This suggest, that it 21 
may not have been an independent parameter. They describe, that G/G genotype variant could 22 
have been associated with other factors, that causes tumor resistance. The fact that they didn’t 23 
find association of SNPA1450G and acute pulmonary toxicity can be explained also, that they 24 
investigated the occurrence of acute pulmonary toxicity, whereas, our study investigated 25 
quantitative features of long-term pulmonary toxicity. Compared to the TC patients of the 26 
Dutch study, our patients were treated with lower cumulative bleomycin doses administered 27 
im., and still had normal kidney function results, possibly showing a major role of BLMH 28 
 8 
genetic polymorphism in inactivating bleomycin. Overall, BLMH gene SNP A1450G 1 
polymorphism seems to have significance on the long-term. Obviously, the different nature of 2 
the diseases may also have contributed to these conflicting results. Limitation of the control 3 
group is, that control patients cannot be matched in elapsed time since treatment with the 4 
investigated patient population. This is because we wanted to show; that BLMH had no role 5 
in those previously treated HL patients, who have not received bleomycin, however such 6 
treatment modality existed only formerly. The authors are aware, that this analysis has several 7 
limitations. We don’t have pharmacokinetic data available in the different genotype cases. 8 
Obviously this was a smaller cohort of patients, therefore replication and validation of our 9 
results needed. Replication in a bigger cohort would result in a situation, when we don’ t need 10 
to collapse heterozygous and homozygous variant carriers. Because bleomycin serum level is 11 
significantly affected by kidney function [14], evaluating bleomycin bioavailability in HL 12 
patients sera and demonstrating pharmacokinetics of bleomycin in patients with BLMH 13 
variations would confirm our results and correlation with BLMH gene SNP A1450G. 14 
Although this current analysis is only discovery-phase, an eventual goal would be to identify 15 
those cases with multiple pulmonary risk factors even in the frontline setting when 16 
brentuximab vedotin should be administered instead of bleomycin, either in standard of care 17 
or because of cost of targeted therapy. Eventually, treatment could be adjusted individually. 18 
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Table 1. Patient characteristics of Hodgkin lymphoma patients. 1 
 2 
         
  
Control  
(no 
bleomycin) 
All bleomycin 
treated 
patients 
p-
value* 
Only ABVD 
treated 
patients 
p-
value** 
Number of 
patients   29 102   68   
Bleomycin dose, 
mg/m2 (median, 
range) 
 0 130 (40-160) N/A 120 (60-160) N/A 
Age, years 
(median, range)  28 (14-57) 30 (14-73) 0.871 30 (15-62) 0.143 
Male/female  16/13 55/47 0.764 40/28 0.740 
Years since 
treatment 
(median, range)  
28 (15-44) 10 (2-25) <0.0001 8 (2-22) <0.0001 
              
Number of 
patients (%)            
Stage early 16 (55.17) 52 (51.00) 0.361 43 (63.24) 0.880 
 advanced 13 (44.83) 50 (49.00)  25 (36.76)  
              
Histology NPLHL 2 (6.90) 3 (2.94) 0.318 3 (4.41) 0.575 
 cHL 27 (93.10) 99 (97.06)  65 (95.59)  
              
  G/G 5 (17.24) 10 (9.80)  6 (8.82)  
BLMH genotype A/G 10 (34.48) 34 (33.33) 0.296 22 (32.35) 0.253 
  A/A 14 (48.28) 58 (58.86)  40 (58.82)  
              
Smokers   5 (17.24) 29 (28.43) 0.645 22 (32.35) 0.673 
Chest 
irradiation   13 (44.83) 49 (48.04) 0.727 31 (45.49) 0.945 
Use of G-CSF   N/A 18 (17.65) N/A 13 (19.12) N/A 
Creatinine 
clearance, 
µmol/min 
(median, range) 
 N/A 72 (47-99) N/A 69 (45-98) N/A 
 3 
 4 
* Comparison of "All bleomycin treated patients" and "Controll group" 5 
** Comparison of "Only ABVD treated patients" and "Controll group 6 
A total of 131 patients were treated with either bleomycin-containing therapy (ABVD, BEACOPP, 7 
COPP/ABV, relapsed/ refractory patients) (n=102) or excluding bleomycin,   regarded  as a control group 8 
(irradiation only, COPP, CVPP) (n=29). Within the bleomycin-treated cohort a total number of 68 patients 9 
 11 
were treated with  ABVD regimen alone. p values are considered significant if <0.05 and  are marked 1 
bold. 2 
N/A – not applicable, ABVD – adriamycin (doxorubicin), bleomycin, vinblastin, dacarbazine, BEACOPP – bleomycin, etoposide, adriamycin 3 
(doxorubicin), cyclophosphamide, oncovin (vincristine), procarbazine, prednisone), COPP/ABV – cyclophophamide, vincristin, prednisone, 4 
procarbazine doxorubicin, bleomycin, vinblastin, COPP – cyclophophamide, vincristin, prednisone, procarbazine, CVPP – cyclophophamide, 5 
vinblastine, prednisone, procarbazine, NLPHL – nodular lmyphocyte predominat Hodgkin lymphoma, cLR – classical lymphocyte rich, cMC – 6 
classical mixed cellularity, cNS – classical nodular sclerosis, cLD – classical lymphocyte depletion, ND – not determined, G-CSF – granulocyte 7 
colony stimulating factor 8 
 12 
Table 2. Allele and genotype frequency of Hodgkin lymphoma patients’. 1 
 2 
Own patients’ data (n=131) 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
“A” is the wild-type and “G” is the mutated allele. Patients were subdivided into subgroups: one 14 
containing the mutated allele: A/G+G/G (45.1%) and the other homogenous for the wild-type allele: 15 
A/A (55.0%). Pts. nr. – Patients number 16 
 17 
Table 3. NCBI SNP database (rs1050565) 18 
 20 
 21 
 22 
 23 
 24 
  25 
“A” is the wild-type and “G” is the mutated allele. Our results are comparable with the NCBI 26 
database.  27 
NCBI – National Center for Biotechnology Information, SNP – Single nucleotide polymorphysm 28 
 29 
Allele frequency 
 A G 
Pts. nr. 188 74 
% 71.8 28.2 
Genotype frequency 
  A/A A/G G/G 
Pts. nr. 72 44 15 
%  55.0 33.6 11.5 
Allele frequency 
 A G 
% 71.8 28.2 
Genotype frequency 
 A/A A/G G/G 
% 41.7 45.8 12.5 
 13 
Table 4. Factors that could potentially affect lung function were equally represented in each treatment subgroup. 1 
  All bleomycin treated patients Only ABVD treated patients Control (no bleomycin) 
  A/G+G/G A/A p A/G+G/G A/A p A/G+G/G A/A p 
Number of patients 43 59  28 40  15 14  
Bleomycin dose, 
mg/m2 (median, range) 140 (40-160) 130 (40-160) 0.440 140 (80-160) 130(60-160) 0.116 0 0 N/A 
Median age, years 
(range) 44 (16-73) 33 (14-62) 0.967 44 (19-58) 33 (15-62) 0.653 26 (14-57) 24 (14-45) 0.756 
Male/female 21/22 34/25 0.424 17/11 23/17 0.792 5/9 10/4 0.158 
Years since treatment 
(median, range) 9 (2-25) 7 (1-25) 0.191 9 (2-16) 7 (1-22) 0.544 30 (14-41) 35 (14-44) 0.401 
Smokers 13 (30%) 16 (27%) 0.350 10 (36%) 12 (30%) 0.403 2 (13%) 3 (21%) 0.792 
Chest irradiation 24 (56%) 25 (42%) 0.209 14 (50%) 17 (43%) 0.544 7 (47%) 6 (43%) 0.880 
Creatinine clearance, 
µmol/min (median, 
range) 
78 (47-92) 72 (48-99) 0.684 77 (45-86) 69 (48-98) 0.776 N/A N/A N/A 
Use of G-CSF 11 (26%) 6 (10%) 0.091 7 (25%) 6 (15%) 0.241 N/A N/A N/A 
 2 
“A” – wild-type, ABVD – adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine, “G” – mutant type, G-CSF – granulocyte-colony stimulating factor 3 
 4 
 5 
 14 
Figure legends 1 
Fig 1. ABVD treated patients. 2 
A total number of 68 patients were treated with ABVD regimen alone. Mean value of 3 
subgroup ± standard error of mean (SEM) is shown. p values are considered significant if 4 
<0.05 and  are marked bold. Significantly more favorable results were seen in the wild-type 5 
A/A genotype group of BLMH SNP A1450G with the St. George Respiratory Questionnaire 6 
(SGRQ) (A.), with lung scintigraphy results on the right side (B.). Spirometry revealed 7 
significantly more favorable forced vital capacity (FVC) and forced expiratory volume in 1 s 8 
(FEV1) results. (C.) Linear regression analysis of BLMH SNP A1450G confirmed these 9 
results for the different test methods. (D.) 10 
“A” – wild-type, ABVD – adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine, DTPA – diethylenetriamine penta-11 
acetic acid, FEV1 – forced expiratory volume in 1 second, FMF – forced mid-expiratory flow, FVC – forced vital capacity, “G” – 12 
mutant type, SGRQ – St. George’s Respiratory Questionnaire 13 
 14 
Fig 2. Control group 15 
The control group contained 29 patients, whose treatment excluded bleomycin. Mean value of 16 
subgroup ± standard error of mean (SEM) is shown. No significant differences were seen 17 
between the A/G+G/G and A/A genotype groups. 18 
“A” – wild-type, DTPA – diethylenetriamine penta-acetic acid, FEV1 – forced expiratory volume in 1 second, FMF – forced mid-19 
expiratory flow, FVC – forced vital capacity, “G” – mutant type; NS – non-significant, SGRQ – St. George’s Respiratory 20 
Questionnaire.  21 
 22 
Supporting information  23 
S1 File 24 
Results were calculated based on the “HL patients” dataset, while patient characteristics were 25 
evaluated based on “Clinicopathological features” data set. 26 
